Janux and BridgeBio Oncology Present Promising Biotech Opportunities

Janux Therapeutics (JANX) is highlighted as a biotech opportunity with next-generation immunotherapy potential, while BridgeBio Oncology Therapeutics (BBOT) is seen as a rising oncology opportunity with KRAS G12C therapy potential. Both companies are attracting attention for their innovative approaches in the biotech sector.